Madison 109 (M109) Syngeneic Model Service for Lung Cancer

The Madison 109 (M109) syngeneic model of lung cancer propagates a historic, anaplastic murine lung carcinoma in fully immunocompetent BALB/c hosts, carrying one of the deepest drug-screening and metastasis pedigrees of any murine line. Alfa Cytology delivers the complete M109 workflow—authenticated cell banking, subcutaneous, intramuscular or orthotopic lung implantation, balanced randomization, scheduled dosing and metastasis-inclusive endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of Madison 109 (M109) Syngeneic Model for Lung Cancer

M109’s roots reach back to 1964, when a spontaneous anaplastic carcinoma was discovered in the lung of a BALB/c mouse—a tumor the historical record describes in quotation-marked spontaneity, reflecting the era’s conventions. Thirteen years later, Schultz and colleagues brought it into continuous culture (In Vitro, 1977), propagating it beyond 300 generations and characterizing a hypotetraploid karyotype of 69–79 chromosomes with a modal number of 78 and three distinct marker chromosomes. Electron microscopy found a highly undifferentiated cell—little rough endoplasmic reticulum, abundant free polysomes, odd-shaped mitochondria, lipid bodies and phagocytic vacuoles—with C-type virus particles, a signature of its vintage. The cells double every 18–19 hours, pile up in culture with high plating efficiency, and transplant subcutaneously at remarkably low inocula into highly metastatic tumors in syngeneic BALB/c mice. A fascinating footnote is the M109ni variant: prolonged intradermal passage selected a less invasive, non-metastatic derivative that serves studies requiring a purely localized primary tumor.

Fig 1. PD-L1 downregulation in the M109 (MAD109) syngeneic lung cancer model — TCGA lung tumors versus normal lung PD-L1 expression, relative PD-L1 transcript levels, PD-L1 protein (NL-20 vs A549 vs H1435), and mouse lung cancer cell line comparison showing MAD109 PD-L1 downregulation relative to normal lung, validating the M109 model as a PD-L1-low refractory lung cancer platform. (Sun, Fan, et al., 2020)

Pharmacologically, M109 is a monument. In the classic 1977 characterization, five hundred thousand cells implanted intramuscularly produced a progressing primary with metastases to lung, spleen and liver—lung deposits visible by three weeks, host death around day 35—and an 82-agent screening program selected actinomycin D, doxorubicin, daunorubicin, procarbazine and the pyran polymer as actives while confirming insensitivity to cytarabine, BCNU, hydroxyurea, the mustards and vincristine; pyran therapy notably delayed metastatic appearance and prolonged survival. Modern usage has added new chapters: cytochalasin B chemotherapy delivered by localized, systemic and liposomal routes; the iron chelator Dp44mT shrinking tumors by roughly half through caspase-3-driven apoptosis; LDL-mimic nanoparticle paclitaxel in forelimb-axilla implants; and the taxane BMS-275183 tested in (BALB/c × DBA/2)F1 hybrid hosts per the era’s conventions. Orthotopically, a needle injection of one million cells into the left lung produces tumors within 10–15 days, with bloody pleural effusion and pleural, pericardial and contralateral-lung spread by day 25 and a median survival of 28 days—and because M109 expresses folate receptor at high levels, circulating tumor cells can be quantified in peripheral blood by folate-receptor-targeted ligand RT-PCR. Caveats frame its use: the anaplastic histology, inconsistent marker expression and lack of defined oncogenic drivers distance it from modern NSCLC taxonomy; C-type particles are a period artifact; and the model is strictly BALB/c-compatible.

Cell Line Information: Madison 109 (M109)

Key characteristics of M109 and its documented derivatives are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and pathology, bioluminescence imaging and flow-cytometry capabilities in-house, Alfa Cytology molds every M109 engagement around the sponsor’s question—selecting flank, intramuscular or orthotopic formats, calibrating inoculum and schedule, and pairing dosing with metastasis counts, CTC monitoring and histological readouts for clean, decision-grade preclinical data.

Workflow of Madison 109 (M109) Syngeneic Model Construction

Construction of the M109 syngeneic model is an implantation workflow whose quality rests on verified cells, vigorous BALB/c recipients, site-matched technique and a disciplined measurement cadence. A standard engagement proceeds as follows:

1. Source and qualify cells: M109 stocks are cleared by mycoplasma PCR and authenticated against the published profile; folate-receptor expression is documented as a targeting baseline, and luciferase labeling is titrated in vitro where imaging readouts are required.
2. Prepare recipients: BALB/c mice (typically 6–8 weeks old) complete acclimation and health screening and are individually marked before implantation.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (commonly 1 × 10⁷/mL for a 100 µL subcutaneous dose; 5 × 10⁵ cells in a small volume for intramuscular metastasis formats; 1 × 10⁶ cells for orthotopic lung injection).
4. Implant: cells are injected subcutaneously into the flank or forelimb axilla with consistent anatomical positioning; intramuscular or orthotopic left-lung needle-injection formats are executed under anesthesia for metastasis-enriched or organ-context designs.
5. Randomize: when flank tumors reach palpability, animals are assigned to groups balanced by tumor volume and body weight; intramuscular and orthotopic cohorts are randomized at implantation.
6. Dose and follow: test articles are administered on schedule; flank tumors are measured with calipers two to three times weekly (volume typically π/6 × length × width × height); orthotopic cohorts are followed by body weight, respiratory signs and pleural-effusion indicators, with survival recorded.
7. Terminate and analyze: primary tumors are resected and weighed; lungs, spleen and liver are inspected for metastatic deposits and confirmed histologically; pleural effusion is measured where present; peripheral blood can be sampled for folate-receptor CTC quantification; tissues enter histopathology, immunohistochemistry, flow cytometry and molecular analysis.

Fig 2. Madison 109 (M109) Syngeneic Model construction workflow.

Case Study-Madison 109 (M109) Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the M109 platform: establishment-phase optimization of inoculum and implant site, in vivo growth tracking by caliper or bioluminescence, conventional and nanoparticle-based intervention studies, and systematic lung, spleen and liver metastasis quantification with matched histological readouts and optional CTC monitoring. Representative growth curves, metastasis datasets and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

A heritage model like M109 rewards teams that know its quirks—from vintage-line drift to folate-receptor targeting—and that is where Alfa Cytology invests:

• Site-flexible execution spanning flank, intramuscular and orthotopic lung formats in BALB/c hosts.
• Authenticated M109 banks with documented folate-receptor baselines and controlled low-passage handling.
• Command of the classic pharmacology: 82-agent screening history and its sensitivity landscape.
• M109ni non-metastatic variant access for localized-primary designs.
• Orthotopic expertise with pleural-effusion monitoring and FR-targeted CTC quantification.
• Nanoparticle and liposomal delivery evaluation reflecting the model’s documented precedents.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the Madison 109 (M109) syngeneic lung cancer model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.